“We’ll be putting initially a small tariff on pharmaceuticals but in one year—one and a half years maximum—it’s going to go ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...

The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to become an oncology powerhouse. | More than 4 years after its first ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...